Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 72% of modeled bridge. Strengths: Revenue per Bed, Occupancy Rate. Risk-adjusted uplift: $6.0M (vs $8.4M modeled).
EBITDA Bridge β 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%β5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $3.2M | $3.2M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $3.1M | $88K | $3.2M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $488K | $1.4M | $1.9M | $6.1M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $102K | $102K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 47.8% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $796K | $1.6M | $2.4M | $3.2M | $3.2M | $3.2M | $3.2M |
| Denial Rate Reduction | $0 | $788K | $1.6M | $2.4M | $3.2M | $3.2M | $3.2M | $3.2M |
| A/R Days Reduction | $0 | $646K | $1.3M | $1.9M | $1.9M | $1.9M | $1.9M | $1.9M |
| Clean Claim Rate | $0 | $51K | $102K | $102K | $102K | $102K | $102K | $102K |
| Cumulative | $0 | $2.3M | $4.6M | $6.8M | $8.4M | $8.4M | $8.4M | $8.4M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $8.4M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 75% / 16.2x | 79% / 18.4x | 83% / 20.5x | 85% / 21.6x | 87% / 22.7x |
| 9.0x | 70% / 14.0x | 74% / 16.0x | 78% / 17.9x | 80% / 18.8x | 82% / 19.8x |
| 10.0x | 65% / 12.3x | 70% / 14.0x | 74% / 15.8x | 75% / 16.6x | 77% / 17.5x |
| 11.0x | 61% / 10.9x | 66% / 12.5x | 70% / 14.0x | 71% / 14.8x | 73% / 15.6x |
| 12.0x | 58% / 9.7x | 62% / 11.2x | 66% / 12.6x | 68% / 13.3x | 70% / 14.0x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 48% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 3.4x, adding 5.1 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $5.6M | β | $5.6M | 3.5% |
| Year 1 | $5.7M | +$5.6M | $11.3M | 7.1% |
| Year 2 | $5.9M | +$8.4M | $14.3M | 9.0% |
| Year 3 | $6.1M | +$8.4M | $14.5M | 9.1% |
| Year 4 | $6.3M | +$8.4M | $14.7M | 9.2% |
| Year 5 | $6.5M | +$8.4M | $14.8M | 9.3% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $1.6M | $2.4M | $3.2M | $3.8M |
| Denial Rate Reductio | $1.6M | $2.4M | $3.2M | $3.8M |
| A/R Days Reduction | $968K | $1.5M | $1.9M | $2.3M |
| Clean Claim Rate | $51K | $76K | $102K | $122K |
| Total | $4.2M | $6.3M | $8.4M | $10.0M |
Peer Context β Where This Hospital Sits
Key metrics vs 103 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 3.5% | -18.2% | -4.8% | 1.8% | P77 |
| Net-to-Gross | 25.2% | 22.9% | 30.7% | 47.8% | P28 |
| Occupancy | 57.0% | 38.5% | 56.9% | 72.4% | P51 |
| Rev/Bed | $3.2M | $500K | $994K | $2.6M | P83 |
| Exp/Bed | $3.1M | $540K | $1.3M | $2.8M | P79 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%β5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR Γ delta Γ avoidable share. Cost levers use claims volume Γ cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.